Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 4293K | — |
Administration before the recommended age for a booster; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 12-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number 4293K, expiry date 31-JUL-2025) for prophylaxis. Previously administered products included Menveo (received 1st dose on an unknown date). On 08-AUG-2024, the patient received the 2nd dose of Menveo. On 08-AUG-2024, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: Administration before the recommended age for a booster). The outcome of the inappropriate age at vaccine administration was unknown. Additional Information: GSK Receipt Date: 11-FEB-2025 A registered nurse contacted GSK to request data about the administration of a second dose of Menveo to a 12 year old male patient which took place on 8th August 2024, months after the initial dose which led to inappropriate age at vaccine administration. The vaccine administration facility was the same as primary reporter.